Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 GlaxoSmithKline 3Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

GlaxoSmithKline 3Q

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GlaxoSmithKline

3Q Revenues: $11.1 billion (+5% in USD, -3% in local currency)

3Q Earnings: $2.7 billion (+2% in USD, -6% in local currency)

YTD Revenues: $33.3 billion (+6% in USD, -3% in local currency)

YTD Earnings: $8.4 billion (+8% in USD, -1% local currency)

Comments: The weak dollar bolstered the appearance of GSK’s results, but the numbers in GBP show a down quarter. Avandia’s safety concerns walloped GSK’s pharma growth in 3Q, with sales dropping 51% to GBP 153 million ($311 million). Avandia sales have dropped 28% in local currency to GBP 717 million ($1.4 billion). Generic competition damaged sales of Zofran (-86%), Flonase (-23%), Wellbutrin XL (-41%), and Coreg IR/CR (-20%). Overall, 3Q pharma sales were down 2% in local currency to GBP 4.6 billion ($9.3 billion), leading the company to announce a new $3.0 billion Operational Excellence series of cuts to improve the bottom line. This will include streamlining its manufacturing network and salesforce, along with “simplification and streamlining of support infrastructure” to cut R&D costs. The program is expected to deliver pre-tax savings of $1.4 billion by 2010.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters